Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 08, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 141,741 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on November 7, 2005, and was advised to the Company on November 8, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries.
Important Facts for Investors
- Transaction Type: Transfer of shares from an employee trust to plan participants.
- Volume: 141,741 Ordinary Shares were transferred.
- Directors Involved: Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop are noted as having an interest in the shares held in the GSK Trust in the same capacity as other employees.
- Financial Data: No financial performance metrics are included in this specific filing.